VALEANT PHARMACEUTICALS INTL I (VRX) Stock News
NYSE:VRX - New York Stock Exchange, Inc. - CA91911K1021
VRX Latest News, Press Relases and Analysis
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
Valeant: It’s More Than Just Dermatology
Valeant gastroenterology business may be undervalued by investors.
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
Bausch Health Releases Annual Corporate Social Responsibility Report
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference
Bausch Health Resolves Legacy SEC Investigation
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients
9 High-Risk Stocks to Buy for Massive Rewards
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.
Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6
Mentions: BHC
9 High-Risk Stocks to Buy for Massive Rewards
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.
6 Valuable Pipeline Drugs With Upcoming Catalysts
Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma, a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster...
H.C. Wainwright Upgrades Valeant Pharm International (VRX) to Buy
According to The Fly, in a new note to investors today, an analyst has provided a rating update for Valeant Pharm International (VRX – Research Report). Ram Selvaraju, an analyst with H.C. Wainwright, has upgraded their rating on VRX to Buy. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
Mentions: BHC
9 High-Risk Stocks to Buy for Massive Rewards
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.
Valeant Pharm International (VRX) Gets a Buy Rating from Cantor Fitzgerald
According to The Fly, a Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Valeant Pharm International (VRX – Research Report) Chen noted: “. Post a beat and raise quarter, we reiterating our
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
Mentions: BHC
Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
Mentions: BHC
Pyxus Stock Could Backfire Over the Longer Term
The Pyxus stock price has rallied, as PYX stock is the latest "hot" pot stock. But the story has some serious question marks.
There’s Just No Reason to Rush Into Cronos Stock
The CRON stock price has been hugely volatile the last few sessions and that likely will continue for some time.
9 High-Risk Stocks to Buy for Massive Rewards
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.
Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Mentions: BHC
International Ophthalmology and Optometry Devices Market Booming With New Growth Opportunities
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent....
Mizuho Sets Expectations on Valeant (VRX) Ahead of Earnings
Valeant (NYSE:VRX) is raring to deliver what Mizuho’s Irina Rivkind Koffler expects will be a solid ...
The post Mizuho Sets Expectations on Valeant (VRX) Ahead of Earnings appeared first on Smarter Analyst.
3 Real Risks That Could Make You Reconsider Buying Celgene Stock
A 40% decline in Celgene stock has led to a cheap headline earnings multiple. But investors need to understand the risks, which include a patent cliff, management questions, and concerns about the pipeline.
2,800 Tuesday and the S&P – Are We There Yet?
66.6 Thousand. That's the volume the S&P's (SPY) ETF hasn't broken since June.
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
5 Pharmaceutical and Biotech Stocks to Consider for July
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Valeant is back on to its old drug-pricing ways
Valeant is using two techniques to raise prices on one of its best-selling drugs: a larger package and a higher per-milligram price.
Mizuho Says Synthetic Biologics IBS Treatment May Be 'Interesting' For Valeant
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals.
Mentions: SYN